-
Bank Ranking
Banks Ratios
Cement Statistics
Cement Ranking
Cement Ratios
Monetary and Economic Statistics
Oil, Gas and Fuel
Macro Economy
Consumer Spending
Inflation
Exports & Imports
Food Prices
Non Food Prices
Construction Materials
Petrochem. Ranking
Petrochem. Ratios
Retail Rankings
Retail Ratios
Grocery Ranking
Grocery Ratios
Top Growth
Dividend History
Almoosa 2025 net profit soars to SAR 236.5M; Q4 at SAR 82M
Almoosa Health Co. reported a net profit surge to SAR 236.5 million for 2025, from SAR 49.4 million in the year-earlier period.
Financials (Million Riyal)
| Item | 2024 | 2025 | Change |
|---|---|---|---|
| Revenues | 1,202.34 | 1,416.29 | 17.8 % |
| Gross Income | 371.72 | 448.60 | 20.7 % |
| Operating Income | 168.66 | 203.03 | 20.4 % |
| Net Income | 49.35 | 236.54 | 379.3 % |
| Average Shares | 35.00 | 44.30 | 26.6 % |
| Earnings Per Share before unusual items (Riyals) | 2.70 | 4.46 | 65.4 % |
| EPS (Riyal) | 1.41 | 5.34 | 278.6 % |
This was primarily driven by higher revenue from increased patient volumes and admissions, as well as a more favorable case mix with a higher proportion of complex and specialized procedures. The increase was also supported by the expansion of clinical services through the addition of new clinics across various specialties, which enhanced service capacity and contributed to higher patient activity.
Profitability was further supported by improved operational efficiency and stronger cost management across the group’s hospitals and medical centers. In addition, the group recorded lower finance costs following the settlement of certain financing facilities earlier in the year after the IPO, which positively impacted the bottom line.
The company’s operating profit for 2025 increased to SAR 225.7 million, following the classification of the loss on investment as a non-operating item.
Net profit for the period was also affected by non-cash items arising from the mark-to-market valuation of derivative instruments and treatment of fair value loss on investments.
Current Quarter Comparison (Million Riyal)
| Item | Q4 2024 | Q4 2025 | Change |
|---|---|---|---|
| Revenues | 332.11 | 387.96 | 16.8 % |
| Gross Income | 119.95 | 120.29 | 0.3 % |
| Operating Income | 69.69 | 49.84 | (28.5 %) |
| Net Income | 8.96 | 52.20 | 482.7 % |
| Average Shares | 35.00 | 44.30 | 26.6 % |
| Earnings Per Share before unusual items (Riyal) | 1.54 | 1.03 | (33.0 %) |
| EPS (Riyal) | 0.26 | 1.18 | 360.3 % |
Q4 2025 net earnings surged to SAR 82 million, compared to SAR 9.01 million in Q4 2024.
On a sequential basis, net profit jumped 58.7% from SAR 51.64 million in Q3 2025.
Total shareholders’ equity rose to SAR 1.92 billion by Dec. 31, 2025, compared to SAR 626.3 million in the prior-year period.
Attached Documents
View other reports
Share Price
| Current | |
| Market Cap (M Riyal) | 5,032.48 |
| Enterprise Value (EV) (M Riyal) | 6,221.73 |
| Shares Outstanding ((M)) | 44.30 |
| Recurring EPS ( Riyal) (TTM) | 4.07 |
| Book Value (BV) ( Riyal) | 43.34 |
| Par Value ( Riyal) | 10.00 |
| Recurring P/E (TTM) | 27.93 |
| P/E (TTM) | 61.06 |
| Price/book | 2.62 |
| Dividend Yield (%) (Last Year) | 1.14 |
| Return on Average Assets (%) (TTM) | 2.2 |
| Return on Average Equity (%) (TTM) | 4.3 |
| EV/Revenues | 4.03 |
Financial results (Million Riyal)
| Period | Revenues | Change | Gross Income | Change | Operating Income | Change |
|---|---|---|---|---|---|---|
| Q1 2025 | 322.98 | 16.5 % | 98.79 | 25.8 % | 48.06 | 56.8 % |
| Q2 2025 | 348.97 | 22.6 % | 112.09 | 49.1 % | 54.14 | 159.0 % |
| Q3 2025 | 356.40 | 15.5 % | 117.40 | 19.7 % | 55.60 | 17.2 % |
| Q4 2025 | 387.96 | 16.8 % | 120.29 | 0.3 % | 49.84 | (28.5 %) |
| 2025 | 1,416.29 | 17.8 % | 448.60 | 20.7 % | 203.03 | 20.4 % |
Profit Performance (Million Riyal)
| Period | Net Income | Change | EPS(Riyal) | Extraordinary Income/Expense | Net Profit Before Unusual Items | EPS(Riyal) |
|---|---|---|---|---|---|---|
| Q1 2025 | 67.22 | 389.7 % | 1.52 | 18.75 | 48.47 | 1.09 |
| Q2 2025 | 67.97 | 5494.3 % | 1.53 | 16.20 | 51.77 | 1.17 |
| Q3 2025 | 65.80 | 135.6 % | 1.49 | - | 65.80 | 1.49 |
| Q4 2025 | 52.20 | 482.7 % | 1.18 | 6.40 | 45.80 | 1.03 |
| 2025 | 236.54 | 379.3 % | 5.34 | 38.86 | 197.68 | 4.46 |
Profitability
| Period | Gross Margin | Adjusted EBITDA margin | Net Margin Before Unusual Items |
|---|---|---|---|
| Q1 2024 | 30.85 % | - | 8.38 % |
| Q2 2024 | 29.94 % | - | 5.77 % |
| Q3 2024 | 31.04 % | 17.91 % | 5.30 % |
| Q4 2024 | 30.92 % | 20.96 % | 7.85 % |
| 2024 | 30.92 % | 20.96 % | 7.85 % |
| Q1 2025 | 31.40 % | 21.77 % | 10.35 % |
| Q2 2025 | 32.68 % | 23.46 % | 13.88 % |
| Q3 2025 | 32.95 % | 23.10 % | 16.18 % |
| Q4 2025 | 31.67 % | 21.46 % | 14.96 % |
| 2025 | 31.67 % | 21.13 % | 13.96 % |
Per Share Data (Riyal)
| Period | Shares Outstanding (M) | EPS (Riyal) | Earnings Per Share before unusual items (Riyal) | Book Value (BV) |
|---|---|---|---|---|
| Q1 2025 | 44.30 | 2.32 | 2.92 | 41.42 |
| Q2 2025 | 44.30 | 3.88 | 4.11 | 41.74 |
| Q3 2025 | 44.30 | 4.74 | 4.97 | 42.89 |
| Q4 2025 | 44.30 | 5.71 | 4.78 | 43.43 |
Multiple Ratios (End of Period Price)
| Period | P/E | Recurring P/E | Price/book |
|---|---|---|---|
| Q1 2025 | 64.70 | 51.51 | 3.63 |
| Q2 2025 | 41.76 | 39.44 | 3.89 |
| Q3 2025 | 35.47 | 33.84 | 3.92 |
| Q4 2025 | 30.69 | 36.68 | 4.04 |
Business Segments (Million Riyal)
Q4 2025
| Period | medical services | Pharmaceuticals | Rehabilitation |
|---|---|---|---|
| Q1 2025 | 214.15 | 74.30 | 34.53 |
| Q2 2025 | 229.60 | 78.06 | 41.31 |
| Q3 2025 | 230.81 | 78.45 | 47.12 |
| Q4 2025 | 242.94 | 87.09 | 57.93 |
Analysts Estimates (Million Riyal)
| Item | Profit (Expected) | Profit (Actual) | Change |
|---|---|---|---|
| Average | 64.00 | 52.20 |
Estimates vs Actual (Million Riyal)
| Item | Profit (Expected) | Profit (Actual) | Change | Profit Before Unusual Items | Change |
|---|---|---|---|---|---|
| SNB Capital | 62.30 | 52.20 | 45.80 | ||
| AlJazira Capital | 65.70 | 52.20 | 45.80 |
Comments {{getCommentCount()}}
Be the first to comment
رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}
{{comment.DisplayName}}
{{comment.ElapsedTime}}